Clinical Study

Nrg-Hn001- Randomized Phase II And Phase III Studies Of Individualized Treatment For Nasopharyngeal Carcinoma Based On Biomarker Epstein Barr Virus (Ebv) Deoxyribonucleic Acid (Dna)

Posted Date: May 15, 2019

  • Investigator: Jordan Kharofa
  • Specialties: Cancer, Head and Neck Cancer, Oncology
  • Type of Study: Drug

The goal of this study is to determine whether substituting adjuvant CDDP and 5-FU with gemcitabine and paclitaxel will result in superior progression-free survival.

Criteria:

To Be Eligible: Patients Must Have Stage Ii-Ivb Nasopharyngeal Cancer, Age 18 Or Older, Nonpregnant, No Prior Invasive Malignancy In Past 3 Years.

Keywords:

Head And Neck Cancer, Nasopharyngeal Carcinoma, Cancer, Head & Neck

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.